Al-Achkar Walid, Wafa Abdulsamad, Moassass Faten, Liehr Thomas
Molecular Biology and Biotechnology Department, Human Genetics Division, Atomic Energy Commission, Damascus, Syria.
Oncol Lett. 2012 May;3(5):1027-1029. doi: 10.3892/ol.2012.623. Epub 2012 Feb 28.
The so-called Philadelphia (Ph) chromosome is present in more than 90% of chronic myeloid leukemia (CML) patients. Approximately, 5-10% of these patients show complex translocations involving a third chromosome in addition to chromosomes 9 and 22. Since at present the majority of CML cases are treated with imatinib, variant rearrangements do not exhibit specific prognostic significance. However, events of therapy resistance remain to be studied. In this study, we report a unique case of CML exhibiting an uncommon t(21;22)(p12;q11). This translocation has been characterized by fluorescence in situ hybridization (FISH) and array-proven multicolor banding (aMCB). Using specific probes for the BCR and ABL genes, results of FISH showed a three-way variant Philadelphia translocation (9;22;21)(q34;q11;p12) with a BCR/ABL fusion residing on the der(22) and the 3'BCR region translocated on the short arm of the derivative chromosome 21. In addition, the aMCB technique is significant in the detection of the breakpoints of genetic changes. The underlying mechanisms and prognostic significance of these changes are discussed.
所谓的费城(Ph)染色体存在于超过90%的慢性髓性白血病(CML)患者中。在这些患者中,约5-10%除了9号和22号染色体外,还显示涉及第三条染色体的复杂易位。由于目前大多数CML病例采用伊马替尼治疗,变异重排不具有特定的预后意义。然而,治疗耐药事件仍有待研究。在本研究中,我们报告了一例独特的CML病例,其表现出罕见的t(21;22)(p12;q11)。这种易位已通过荧光原位杂交(FISH)和阵列验证的多色带型分析(aMCB)进行了表征。使用针对BCR和ABL基因的特异性探针,FISH结果显示了一种三体变异型费城易位(9;22;21)(q34;q11;p12),其中BCR/ABL融合位于der(22)上,3'BCR区域易位至衍生染色体21的短臂上。此外,aMCB技术在检测基因变化的断点方面具有重要意义。我们还讨论了这些变化的潜在机制和预后意义。